Evidence map›Paper›PMID 40108464›Full record

ArticleNature2025

Oncolytic virus VG161 in refractory hepatocellular carcinoma.

Yinan Shen, Xueli Bai, Qi Zhang, Xingmei Liang, Xinyan Jin, Zeda Zhao, Wei Song, Qian Tan, Ronghua Zhao, William Jia and 30 more

Erratum issuedAbstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. DamageZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors.

Yinan Shen *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xueli Bai *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-2934-0880
Qi Zhang *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xingmei Liang *Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xinyan JinDepartment of Ultrasound Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zeda ZhaoZhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
Wei SongZhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
Qian TanShanghai Virogin Biotech, Shanghai, China.
Ronghua ZhaoShanghai Virogin Biotech, Shanghai, China.
William JiaShanghai Virogin Biotech, Shanghai, China.
Shanzhi GuDepartment of Interventional Radiology, Hunan Cancer Hospital, Changsha, China.
Guoming ShiDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-3817-9117
Ziwei ZhengShanghai Virogin Biotech, Shanghai, China.
Guyue WeiDepartment of Ultrasound Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Youlei WangKey Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Tian FangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yuwei LiDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zijun WangZhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
Zifan YangZhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
Sida GuoZhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
Danni LinDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Fang WeiZhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
Lei WangDepartment of Radiotherapy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaoli SunDepartment of Radiotherapy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Aijun QinShanghai Virogin Biotech, Shanghai, China.
Longshen XieCNBG-Virogin Biotech (Shanghai), Shanghai, China.
Yeting QiuShanghai Virogin Biotech, Shanghai, China.
Wenqing BaoShanghai Virogin Biotech, Shanghai, China.
Shah RahimianVirogin Biotech Canada, Richmond, British Columbia, Canada.
Manu SinghVirogin Biotech Canada, Richmond, British Columbia, Canada.ORCID 0000-0001-9396-1502
Yanal MuradVirogin Biotech Canada, Richmond, British Columbia, Canada.
Jianying ShangShanghai Virogin Biotech, Shanghai, China.
Min ChuShanghai Virogin Biotech, Shanghai, China.
Maoliang HuangCNBG-Virogin Biotech (Shanghai), Shanghai, China.
Jun DingShanghai Virogin Biotech, Shanghai, China.
Wei ChenDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yufu YeDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yiwen ChenDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiang LiDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Tingbo LiangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. liangtingbo@zju.edu.cn.ORCID 0000-0003-0143-3353

Funding

Medical Health Science and Technology Project of Zhejiang ProvinceNational Key Research and Development Program of ChinaNational Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province/Exploration Project
6 · The paper itself

Abstract

Hepatocellular carcinoma remains a life-threatening malignancy with limited therapeutic options following the failure of second-line treatments

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsOncolytic VirotherapyOncolytic VirusesAgedB7-H1 AntigenFemaleHumansMaleMiddle AgedTreatment OutcomeTumor MicroenvironmentB7-H1 AntigenCD274 protein, human

Identifiers

PMID40108464

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.